Triptorelin acetate administration in early pregnancy: case reports and review of the literature

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 80, Issue 2, 1998, Pages 143-149

  Chardonnens, Didier ^a   Sylvan, Kirsten ^a   Walker, Dilys ^a   Bischof, Paul ^a   Sakkas, Denny ^a   Campana, Aldo ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Assisted reproduction; Early pregnancy; GnRH agonist; IVF; Triptorelin acetate

Indexed keywords

HUMAN MENOPAUSAL GONADOTROPIN; TRIPTORELIN;

ADULT; ARTICLE; CASE REPORT; ESTRADIOL BLOOD LEVEL; FEMALE; FERTILIZATION IN VITRO; FIRST TRIMESTER PREGNANCY; FOLLOW UP; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; PREGNANCY COMPLICATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0032189193     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(98)00109-2     Document Type: Article

References (71)

1. [1] Smitz J, Ron-El R, Tarlatzis BC. The use of gonadotrophin releasing hormone agonists for in vitro fertilization and other assisted procreation techniques: Experience from three centres. Hum Reprod 1992;7(Suppl. 1):49-66.
2. [2] Devroey P, Smitz J, van den Abbeel E, Camus M, Wisanto A, van Steirteghem AC. The use of LHRH analogues in IVF/GIFT/ZIFT programmes. Gynecol Endocrinol 1989;3(Suppl. 2):63-8.
3. [3] Neveu S, Hedon B, Bringer J, Chinchole JM, Arnal F, Humeau C. Ovarian stimulation by a combination of gonadotrophin-releasing hormone agonist and gonadotrophins for in vitro fertilization. Fertil Steril 1987;47:639-43.
4. [4] Insler V, Potashnik G, Lunenfeld E, Meizner I, Levy J. The combined suppression /stimulation therapy in IVF-ET programmes. Expectations and facts. Hum Reprod 1989;4(Suppl.8):47-51.
5. [5] Hughes EG, Sagle MA, Fedorkow DM, Van der Koppel P, Daya S, Collins JA. The routine use of gonadotrophin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertil Steril 1992;58:888-96.
6. [6] Herman A, Ron-El R, Golan A, Nahum MT, Soffer Y, Caspi E. Follicle cysts after menstrual versus midluteal administration of gonadotrophin-releasing hormone analog in in vitreo fertilization. Fertil Steril 1990;53:854-8.
7. [7] Balen AH, Tan SL, MacDougall J, Jacobs HS. Miscarriage rates following in-vitro fertilization are increased in women with policystic ovaries and reduced by pituitary desensitization with buserelin. Hum Reprod 1993;8:1148-51.
8. [8] Golan A, Ron-El R, Herman A, Weinraub Z, Soffer Y, Caspi E. Fetal outcome following inadvertent administration of long-acting DTRPT GnRH microcapsules during pregnancy: a case report. Hum Reprod 1990;5:123-4.
9. [9] Herman A, Ron-El R, Golan A, Nachum H, Soffer Y, Capsi E. Impaired corpus luteum function and other undesired results of pregnancies associated with inadvertent administration of a long-acting agonist of gonadotrophin-releasing hormone. Hum Reprod 1992;7:465-8.
10. [10] HarToov J, Brenner SH, Jaffa A, Yavetz H, Peyser MR, Lessing JB. Pregnancy during long-term gonadotrophin-releasing hormone agonist therapy associated with clinical pseudomenopause. Fertil Steril 1993;59:446-7.
11. [11] Weissman A, Shoham Z. Favourable pregnancy outcome after administration of a long-acting gonadotrophin-releasing hormone agonist in the mid-luteal phase. Hum Reprod 1993;8:496-7.
12. [12] Elefant E, Biour B, Blumberg-Tick J, Roux C, Thomas F. Administration of a gonadotrophin-releasing hormone agonist during pregnancy: follow-up of 28 pregnancies exposed to Triptorelin. Fertil Steril 1995;63:1111-3.
13. [13] Balasch J, Martinez F, Jove I, Cabre L, Coroleu B, Barri PN, Vanrell JA. Inadvertent gonadotrophin-releasing hormone agonist (GnRH-a) administration in the luteal phase may improve fecundity in in-vitro fertilization patients. Hum Reprod 1993;8:1148-51.
14. [14] Hull MGR, The causes of infertility and relative effectiveness of treatment. In: Templeton AA, Drife JO, editors. Infertility. New York: Springer, 1992:33-62.
15. [15] Smitz J, Erard P, Camus M, Devroey P, Tournaye H, Wisanto A, Van Steirteghem AC. Pituitary gonadotrophin secretory capacity during the luteal phase in superovulation using GnRH-agonists and HMG in a desensitization of flare-up protocol. Hum Reprod 1992;7:1225-9.
16. [16] Kang IS, Kuehl TJ, Siler-Khodr TM. Effect of treatment with gonadotrophin-releasing hormone analogues on pregnancy outcome in the baboon. Fertil Steril 1989;52:846-53.
17. 2 10]-luteinizing hormone releasing hormone ethylamide in normal women. Fertil Steril 1979;32:646-51.
18. [18] Skarin G, Nillius SJ, Wide L. Failure to induce abortion of early human pregnancy by high doses of a superactive LRH agonist. Contraception 1982;26:457-61.
19. [19] Tolis G, Cornaru-Schally AM, Mehta AE, Schally AV. Failure to interrupt established pregnancy in humans by d-tryptophan-6-luteinizing hormone-releasing hormone. Fertil Steril 1981;36:241-2.
20. [20] Sopelak VM, Hodgen GD. Infusion of gonadotrophin-releasing hormone agonist during pregnancy: maternal and fetal responses in primates. Am J Obstet Gynecol 1987;156:755-60.
21. [21] Smitz J, Devroey P, Camus M, Deschacht J, Khan I, Staessen C, Van Waesberge L, Wisanto A, Van Steirteghem AC. The luteal phase and early pregnancy after combined GnRH-agonist/hMG treatment for superovulation in IVF or GIFT. Hum Reprod 1988;3:590-5.
22. [22] Porcu E, Dal Prato L, Seracchioli R, Fabbri R, Longhi M, Flamigni C. Comparison between depot and standard release triptoreline in in vitro fertilization: pituitary sensitivity, luteal function, pregnancy outcome and perinatal results. Fertil Steril 1994;62:126-32.
23. [23] Devreker F, Govaerts I, Bertrand E, Van den Bergh M, Gervy C, Englert Y. The long-acting gonadotrophin releasing hormone analogues impaired the implantation rate. Fertil Steril 1996;65:122-6.
24. [24] Bramley TA, Menzies CS, Baird DT. Specific binding of gonadotrophin-releasing hormone and an agonist to human corpus luteum homgenates: characterization, properties and luteal phase levels. J Clin Endocrinol Metab 1985;61:834-41.
25. [25] Bramley TA, Stirling D, Swanston IA, Menzies CS, Mc Neily AS, Baird DT. Specific binding sites for gonadotrophin-releasing hormone, LH/chorionic gonadotrophin, low-density lipoprotein, prolactin and FSH in homogenates of human corpus luteum. II: concentration throughout the luteal phase of the menstrual cycle and early pregnancy. J Endocrinol 1987;113:317-27.
26. [26] Casper RF, Erickson GF, Rebar RW, Yen SSC. The effect of luteinizing hormone-releasing factor and its agonist on cultured human granulosa cells. Fertil Steril 1982;37:406-9.
27. [27] Casper RF, Erickson GF, Yen SSC. Studies on the effect of gonadotrophin-releasing hormone and its agonist on human luteal steroidogenesis in vitro. Fertil Steril 1984;42:39-43.
28. [28] Tureck RW, Mastroianni L, Blasco L, Strauss JF. Inhibition of granulosa cell progesterone secretion by a gonadotrophin-relesing hormone agonist. J Clin Endocrinol Metab 1982;54:1078-80.
29. [29] Parinaud J, Beaur A, Bourreau E, Vieitez G, Pontonnier G. Effect of luteinising hormone-releasing hormone agonist (Buserelin) on steroidogenesis of cultured human preovulatory granulosa cells. Fertil Steril 1988;50:597-602.
30. [30] Bussenot I, Azoulay-Barjonet C, Parinaud J. Modulation of steroidogenesis of cultured human granulosa-lutein cells by gonadotrophin-releasing hormone analogs. J Clin Endocrinol Metab 1993;76:1376-9.
31. [31] Parinaud J, Oustry P, Perineau M, Reme JM, Monrozies X, Pontonnier G. Randomized trial of three luteinizing hormone-releasing hormone analogs use for ovarian stimulation in an in vitro-fertilization program. Fertil Steril 1992;57:1265-8.
32. [32] Guerrero HE, Stein P, Asch RH, Polak de Fried E, Tesone M. Effect of gonadotropin-releasing hormone agonist on luteinizing hormone receptors and steroidgenesis in ovarian cells. Fertil Steril 1993;59:803-9.
33. [33] Gaetje R. Influence of gonadotrophin releasing hormone (GnRH) and a GnRH-agonist on granulosa cells steroidogenesis. Clin Exp Obstet Gynecol 1994;21:164-9.
34. [34] Bramley TA, Mc Phie CA, Menzies GS. Human placental gonadotrophin-releasing hormone (GnRH) Binding sites: I. Characterization, properties and ligand specificity. Placenta 1992;13:555-81.
35. [35] Siler-Khodr TM, Khodr GS, Valenzuela G, Rhode J. Gonadotrophin-releasing hormone effects on placental hormones during gestation: I. Alpha-human chorionic gonadotrophin, human chorionic gonadotrophin and human somatomammotropin. Biol Reprod 1986;34:245-54.
36. [36] Merz WE, Erlewein C, Licht P, Harbarth P. The secretion of human chorionic gonadotrophin as well as the alpha-and beta messenger ribonucleic acid levels are stimulated by exogenous gonadoliberin pulses applied to first trimester placenta in a superfusion culture system. J Clin Endocrinol Metab 1991;73:84-92.
37. [37] Lin LS, Roberts VJ, Yen SS. Expression of Human Gonadotrophin-Releasing Hormone Receptor Gene in the Placenta and Its Functional Relationship to Human Chorionic Gonadotrophin Secretion. J Clin Endocrinol Metab 1995;80:580-4.
38. [38] Barnea ER, Kaplan M. Spontaneous, gonadotrophin-releasing hormone-induced, and progesterone-inhibited pulsatile secretion of human chorionic gonadotrophin in the first trimester placenta in vitro. J Clin Endocrinol Metab 1989;69:215-7.
39. [39] Kim SJ, Namkoong SR, Lee JW, Jung JK, Kang BC, Park JS. Response of human chorionic gonadotrophin to luteinizing hormone-releasing hormone stimulation in the culture media of normal human placenta, choriocarcinoma cell lines, and in the serum of patients with gestational trophoblastic disease. Placenta 1987;8:257-63.
40. [40] Barnea ER, Kaplan M, Naor Z. Comparative stimulatory effect of gonadotrophin releasing hormone (GnRH) and GnRH agonist upon pulsatile human chorionic gonadotrophin secretion in superfused placental explants: reversible inhibition by a GnRH antagonist. Hum Reprod 1991;6:1063-9.
41. [41] Mathialagan N, Rao AJ. Gonadotrophin releasing hormone (GnRH) stimulates bothe secretion and synthesis of human chorionic gonadotrophin (hCG) by first trimester human placental minces. Biochem Int 1986;13:757-65.
42. [42] Bergquist C, Nillius SJ, Wide L. Luteolysis induced by a luteinizing hormone-releasing hormone agonist is prevented by human chorionic gonadotrophin. Contraception 1980;22:341-7.
43. [43] Jones GS. Corpus luteum:composition and function. Fertil Steril 1990;54:21-6.
44. [44] Chang SY, Soong YK. Unexpected pregnancies exposed to leuprolide acetate administered after the mid-luteal phase for ovarian stimulation. Hum Reprod 1995;10:204-6.
45. [45] French FE, Bierman JM. Probability of fetal mortality. Public Health Rep 1960;77:835-47.
46. [46] Salat-Baroux J. Recurrent spontaneous abortions. Reprod Nutr Dev 1988;28:1555-68.
47. [47] Chong AP, Keene ME, Forte CC, Dileo PE, Brown PC, McGary JG. Incidence of spontaneous abortion among treated infertility patients. Int J Fertil 1991;36:219-21.
48. [48] Thomas GB, McNeilly AS, Gibson F, Brooks AN. Effects of pituitary-gonadal suppression with a gonadotrophin-releasing hormone agonist on fetal gonadotrophin secretion, fetal gonadal development and maternal steroid secretion in the sheep. J Endocrinol 1994;141:317-24.
49. [49] Kaplan SL, Grumbach MM, Aubert ML. The ontogenesis of pituitary hormones and hypothalamic factors in the human fetus: Maturation of central nervous system regulation of anterior pituitary function. Recent Prog Horm Res 1976;32:161-243.
50. [50] Dumesic DA, Pohl H, Kamel F, Terasawa E. Increase in luteinizing hormone content occurs in cultured human fetal pituitary cells exposed to gonadotrophin-releasing hormone. J Clin Endocrinol Metab 1990;70:606-14.
51. [51] Rossmanith WG, Swartz WH, Tueros VS, Yen SSC, Rasmussen DD. Pulsatile GnRH-stimulated LH release from human fetal pituitary in-vitro: sex-associated differences. Clin Endocrinol 1990;33:719-27.
52. [52] Sorem KA, Smikle CB, Spencer DK, Yoder BA, Graveson MS, Siler-Khodr T. Circulating maternal corticotropin-releasing hormone and gonadotropin-releasing hormone in normal and abnormal pregnancies. Am J Obst Gynecol 1996;175:912-6.
53. [53] Ron-El R, Golan A, Herman A, Raziel A, Soffer Y, Caspi E. Midluteal gonadotrophin-releasing hormone analog administration in early pregnancy. Fertil Steril 1990;53:572-4.
54. [54] Jackson AE, Curtis P, Amso N, Shaw RW. Expsosure to LHRH agonists in early pregnancy following the commencement of midluteal buserelin for IVF stimulation. Hum Reprod 1992;7:1222-4.
55. [55] Calhill DJ, Fountain SA, Fox R, Flemming CF, Brinsden PR, Hull MGR. Outcome of inadvertent administration of a gonadotrophin-releasing hormone agonist (buserelin) in early pregnancy. Hum Reprod 1994;9:1243-6.
56. [56] Abu-Heija AT, Fleming R, Yates RWS, Coutts JRT. Pregnancy outcome following exposure to gonadotropin-releasing hormone agonist during early pregnancy: comparisons in patients with normal and elevated luteinizing hormone. Hum Reprod 1995;10:3317-9.
57. [57] Lancaster PAL, Shafir E. High incidence of neural tube defects after assisted conception (Abstract 083). Hum Reprod 1996;11:39.
58. [58] Martinez F, Barri PN, Coroleu V. Case report: accidental GnRH agonist administration during early pregnancy. Hum Reprod 1988;3:669.
59. [59] Serafini P, Batzofin J, Kerin J, Marrs R. Pregnancy: a risk to initiation of leuprolide acetate during the luteal phase before controlled ovarian hyperstimulation. Fertil Steril 1988;50:371-2.
60. [60] Chetkovski RJ, Kruse RL, Nass TE. Improved pregnancy outcome with the addition of leuprolide acetate to gonadotrophins for in vitro fertilisation. Fertil Steril 1989;52:250-5.
61. [61] Dicker D, Goldman JA, Vagman I, Eckstein N, Ayalon D. Pregnancy outcome following early exposure to maternal luteinizing-hormone-releasing hormone agonist (buserelin). Hum Reprod 1989;4:250-1.
62. [62] Forman R, Robinson J, Egan D, Ross C, Gosden B, Barlow D. Ectopic pregnancy after luteal phase initiation of gonadotrophin-releasing hormone analog before in-vitro fertilization. Fertil Steril 1990;54:169-70.
63. [63] Isherwood PJ, Ibrahim ZHZ, Matson PL, Morroll DR, Burslem RW, Lieberman BA. Endocrine changes in woman conceiving during treatment with an LHRH agonist. Hum Reprod 1990;5:409-12.
64. [64] Lejeune B, Barlow P, Puissant F, Delvigne A, Vanrysselberg M, Leroy F. Use of buserelin acetate in an in vitro fertilisation program: a comparison with classical clomiphene citrate-human menopausal gonadotrophin treatment. Fertil Steril 1990;54:475-81.
65. [65] Smitz J, Camus M, Devroey P, Bollen N, Tournaye H, Van Steirteghem AC. The influence of inadvertent intranasal buserelin administration in early pregnancy. Hum Reprod 1991;6:290-3.
66. [66] Ghazi DM, Kemman E, Hammond JM. Normal pregnancy outcome after early maternal exposure to gonadotrophin releasing hormone agonist. A case report. J Reprod Med 1991;36:173-4.
67. [67] Lockwood GM, Robinson JN, Barlow DH. Pregnancy outcome following inadvertent luteal phase initiation of gonadotrophin-releasing hormone agonist (GnRH-a) treatment in superovulation cycles (A103). J Reprod Fertil 1992;10:54.
68. [68] Gonen Y, Dirnfeld M, Abramovici H. Outcome of pregnancies inadvertently exposed to gonadotrophin-releasing hormone analogues (GnRH-a) in early gestation. J Assist Reprod Genet 1993;10:437-9.
69. [69] Wilshire GB, Emmi AE, Gagliardi CC, Weiss G. Gonadotrophin-releasing hormone agonist administration in early human pregnancy is associated with normal outcomes. Fertil Steril 1993;60:980-3.
70. [70] Young DC, Snabes MC, Poindexter AN. GnRH Agonist Exposure During the First Trimester of Pregnancy. Obstet Gynecol 1993;81:587-9.
71. [71] Gartner B, Moreno C, Marinaro A, Remohi J, Simòn C, Pellicer A. Accidental exposure to daily long-acting gonadotrophin-releasing hormone analogue administration and pregnancy in an in-vitro fertilization cycle. Hum Reprod 1997;12:2557-9.